Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI

Published:2022-10 Issue:5 Volume:20 Page:496.e1-496.e9
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Watson Alexander S,Gagnon Richard,Batuyong Eugene,Alimohamed Nimira,Lee-Ying Richard

Funder

Sanofi Genzyme

Sanofi

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference38 articles.

1. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2012

2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302);Rathkopf;Eur Urol,2014

3. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;New England J Med,2014

4. Abiraterone and increased survival in metastatic prostate cancer;de Bono;New England J Med,2011

5. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-992. doi:10.1016/S1470-2045(12)70379-0

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP